Andreanna Burman; Monica E. Brown; Yilin Yang; Michael Momoh; Francisca Adeniran; Cynthia Ramos; Ken S. Lau; Linda C. Samuelson; Mitchell D. Shub; Joseph T. Roland; Izumi Kaji (2026).Ìý.ÌýStem Cell Reports, 21(3), 102820.Ìý
This study investigates the role of a protein calledÌýMYO5B (myosin Vb)Ìýin the intestine, particularly in early-stage cells that give rise to the intestinal lining, known asÌýintestinal stem and progenitor cells. Mutations in MYO5B cause a rare genetic condition calledÌýmicrovillus inclusion disease (MVID), which leads to severe, lifelong diarrhea because the intestine cannot properly absorb nutrients. While previous research showed that MYO5B is important for forming the brush border (the surface of intestinal cells that helps with absorption), its specific role in stem cells was not well understood.
To explore this, the researchers created specialized mouse models in which MYO5B was gradually lost in intestinal crypt cells—the regions where stem cells reside and continuously produce new intestinal cells. They found that without MYO5B, these stem cells lost their normal identity and instead shifted toward aÌýtransit-amplifying (TA) state, meaning they multiplied rapidly but did not fully mature into functional cells. As a result, the intestinal tissue showed excessive cell growth (hyperproliferation) but poor differentiation (incomplete development into specialized cell types). The study also found disruptions inÌýmitochondriaÌý(the cell’s energy producers) andÌýfatty acid metabolism, suggesting that energy processing problems may contribute to these abnormalities.
Importantly, similar patterns were observed in tissue samples from patients with MVID, including an expanded region of rapidly dividing cells and shortened intestinal structures (villus blunting), which impair nutrient absorption. Overall, the findings show that MYO5B plays a crucial role in maintaining healthy intestinal stem cell function, including proper cell growth, maturation, and metabolism, helping explain how its loss leads to disease.

Figure 1ÌýLrig1Δ²Ñ³Û°¿5µþÌýmice are a model of progressive MYO5B deficiency originating in the small intestinal crypt
(A) Experimental timeline of tamoxifen administration (TMX) on day 0 to induce theÌýLrig1-Cre recombinase and the collection of intestinal tissues on days 3 and 5. MYO5B loss and corresponding YFP+ lineage cells are depicted in green.
(B) Changes in mouse body weight following TMX administration. Daily results are presented as mean ± SEM;ÌýNÌý= 5–9 mice per group.Ìý∗∗∗∗pÌý< 0.0001 by two-way ANOVA with Tukey’s test. Asterisk colors depict significances between Lrig1Δ²Ñ³Û°¿5µþand M5B f/f (black) orÌýLrig1-CreERT2;ÌýM5B fl/+Ìý(gray).
(C) Gastrointestinal tract from day 5 control and Lrig1Δ²Ñ³Û°¿5µþÌýmice. Scale bars, 1 cm.
(D) Duodenal histology with Alcian blue-PAS (AB-PAS) staining and MYO5B immunostaining (inverted). Immunostaining illustrates a decrease in targeted epithelial MYO5B expression, and unclassified non-epithelial signal is evident in MYO5B-deficient lamina propria tissues. Example crypts outlined in yellow dashes. Scale bars, 50 μm.
(E) Quantification of crypt and villus lengths from AB-PAS-stained mouse tissues. Mean ± SEM;ÌýNÌý= 5–10 mice per group.Ìý∗∗pÌý< 0.01,Ìý∗∗∗pÌý< 0.001,Ìý∗∗∗∗pÌý< 0.0001 by two-way ANOVA with Dunnett’s test vs. control. Asterisk colors indicate significances in villus (gray) or crypt (yellow) values.
(F) Immunostaining for SGLT1, YFP, and ACTG1 in the mouse duodenum. Scale bars, 50 μm.
(G) Control (adult and pediatric) and pediatric MVID patient small intestinal tissues with multiplexed immunostaining for PCNA (proliferative marker), ACTG1 or Ezrin (brush border), CTNNB1 (basolateral membrane), DEF5A (Paneth cell), and nuclei. Scale bars, 50 μm.